News | December 24, 2024
Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Subscribe To Our Newsletter & Stay Updated
